Issue: August 2024
Fact checked byShenaz Bagha

Read more

June 13, 2024
2 min read
Save

Higher steroid dose improves lupus nephritis renal outcomes, raises mortality risk

Issue: August 2024
Fact checked byShenaz Bagha
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Higher glucocorticoid doses improved lupus nephritis treatment response but increased serious infections and death.
  • Pulses led to greater rates of response and death, but not serious infection.

Patients with lupus nephritis who receive higher initial doses of glucocorticoids demonstrate improved renal outcomes, albeit with increased serious infection and mortality risks, according to data published in Arthritis & Rheumatology.

“Glucocorticoids are a cornerstone in lupus nephritis therapy, and it is known that in combination with immunosuppression they can improve kidney outcomes, but can also increase the risk for infections,” Gabriel Figueroa-Parra, MD, an assistant professor of rheumatology at the Autonomous University of Nuevo León, in Mexico, told Healio. “There is remarkable lack of evidence to inform the appropriate dosing of glucocorticoids during the initial therapy of lupus nephritis. Appropriate tailoring of glucocorticoids is critically important.”

Enlarge 

To examine the impact glucocorticoid regimens have on renal response, infections and mortality in patients with lupus nephritis, Figueroa-Parra and colleagues conducted a systematic review and meta-analysis. The researchers analyzed 50 control arms from 37 randomized controlled trials — featuring a total of 3,231 patients with biopsy-proven lupus nephritis — and evaluated protocolized regimens of glucocorticoids with mycophenolic acid analogs or cyclophosphamide.

The primary outcomes were complete response — defined as proteinuria under 0.5 grams during a period of 24 hours and stabilization of serum creatinine — as well as serious infections and all-cause death. The starting glucocorticoid dose was analyzed as a continuous variable via meta-regression.

According to the researchers, the meta-regression predicted that starting at 25 mg per day of oral prednisone, without methylprednisolone pulses, would yield a complete response rate of 19.5% (95% CI, 7.3-31.5) at 6 months. The prediction increased to 34.6% (95% CI, 16.9-52.3) when starting at 60 mg per day without pulses.

However, the 60 mg prednisone dose also increased the predicted serious infection rate to 12.1% (95% CI, 9.3-14.9), vs. 3.2% (95% CI, 2.4-4) with the 25 mg dose, and the predicted death rate to 2.7% (95% CI, 0-5.3), vs. 0.2% (95% CI, 0-0.4) with the lower dose.

Meanwhile, the addition of glucocorticoid pulses resulted in greater rates of complete response and death, but not serious infections, according to the researchers.

“This study is relevant for clinical practice because it showed the trade-offs of treating lupus nephritis with glucocorticoids when used with mycophenolate mofetil or cyclophosphamide — the standard of care,” study co-author Ali A. Duarte-Garcia, MD, of the Mayo Clinic, told Healio. “Higher doses of glucocorticoids result in higher rates of complete renal response but also higher rates of infection and death.”

Figueroa-Parra added that the results represent “the best available evidence to inform decision-making regarding the initial dose of glucocorticoids in patients with lupus nephritis.”

“Our results confirm what is known, higher glucocorticoid doses are more effective and carry a higher risk of infection,” he said. “However, we did not expect that mortality would also be increased or show a dose-response gradient. We neither expected that the use of IV pulses was going to be an effect modifier for mortality.”